Cargando…

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review

Schizophrenia (SCZ) is a severe mental disorder with high morbidity and lifetime disability rates. Patients with SCZ have a higher risk of developing metabolic comorbidities such as obesity and diabetes mellitus, leading to increased mortality. Antipsychotics (APs), which are the mainstay in the tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Raghunath, Stogios, Nicolette, Smith, Emily, Lee, Jiwon, Maksyutynsk, Kateryna, Au, Emily, Wright, David C., De Palma, Giada, Graff-Guerrero, Ariel, Gerretsen, Philip, Müller, Daniel J., Remington, Gary, Hahn, Margaret, Agarwal, Sri Mahavir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118432/ https://www.ncbi.nlm.nih.gov/pubmed/35600753 http://dx.doi.org/10.1177/20451253221096525

Ejemplares similares

Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
por: Stogios, Nicolette, et al.
Publicado: (2021)

Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls
por: Stogios, Nicolette, et al.
Publicado: (2022)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis
por: Wu, Sally, et al.
Publicado: (2023)

Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review
por: Stogios, Nicolette, et al.
Publicado: (2020)

S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE
por: Agarwal, Sri Mahavir, et al.
Publicado: (2020)

Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia
por: Itahashi, Takashi, et al.
Publicado: (2021)

Non-invasive neuromodulation of dorsolateral prefrontal cortex to reduce craving in alcohol use disorder: A meta-analysis
por: Sorkhou, Maryam, et al.
Publicado: (2022)

Favourable cognitive changes observed with metabolic improvements in a patient with severe mental illness
por: van Reekum, Emma A, et al.
Publicado: (2023)

S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS
por: Costa-Dookhan, Kenya, et al.
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY
por: Mahavir Agarwal, Sri, et al.
Publicado: (2020)

T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
por: Kanji, Sarah, et al.
Publicado: (2018)

Metabolic Syndrome in Schizophrenia: Theoretical, Clinical and Translational Perspectives
por: Agarwal, Sri Mahavir, et al.
Publicado: (2013)

S225. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OR PREVENTION OF WEIGHT GAIN IN SCHIZOPHRENIA
por: Agarwal, Sri Mahavir, et al.
Publicado: (2018)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

F178. NEUROANATOMICAL PROFILES OF TREATMENT-RESISTANCE IN PATIENTS WITH SCHIZOPHRENIA
por: Plitman, Eric, et al.
Publicado: (2018)

S175. AMOTIVATION IS ASSOCIATED WITH SMALLER VENTRAL STRIATUM VOLUMES IN OLDER PATIENTS WITH SCHIZOPHRENIA
por: Caravaggio, Fernando, et al.
Publicado: (2018)

Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia
por: Kim, Julia, et al.
Publicado: (2023)

Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia
por: Iwata, Yusuke, et al.
Publicado: (2021)

S16. GLUTAMATERGIC NEUROMETABOLITE LEVELS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA: A CROSS-SECTIONAL 3T PROTON MRS STUDY
por: Iwata, Yusuke, et al.
Publicado: (2018)

S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA
por: Fervaha, Gagan, et al.
Publicado: (2018)

Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia
por: Costa-Dookhan, Kenya A., et al.
Publicado: (2021)

Differential Methylation Analysis of Suicidal Ideation Severity in Schizophrenia with the Illumina MethylationEPIC Array
por: Wang, Kevin Z., et al.
Publicado: (2022)

Cognitive Mapping Deficits in Schizophrenia: A Critical Overview
por: Bose, Anushree, et al.
Publicado: (2014)

Hidden Role of Gut Microbiome Dysbiosis in Schizophrenia: Antipsychotics or Psychobiotics as Therapeutics?
por: Munawar, Nayla, et al.
Publicado: (2021)

Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol
por: Agarwal, Sri Mahavir, et al.
Publicado: (2023)

Drug Attitude, Insight, and Patient’s Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey
por: Nagai, Nobuhiro, et al.
Publicado: (2020)

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Foussias, George, et al.
Publicado: (2018)

Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D(2/3) Receptors in the Ventral Striatum of Healthy Nonobese Humans
por: Caravaggio, Fernando, et al.
Publicado: (2015)

T174. ANTIPSYCHOTICS AND THE MICROBIOME
por: Chen, Anderson, et al.
Publicado: (2020)

Executive Dysfunction among Children with Antipsychotic Treated Schizophrenia
por: Wiguna, Tjhin, et al.
Publicado: (2014)

Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity
por: Gerretsen, Philip, et al.
Publicado: (2019)

T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bowden, Sylvie, et al.
Publicado: (2020)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Transcranial Direct Current Stimulation in Schizophrenia
por: Agarwal, Sri Mahavir, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2tqtm3eogn333h7v0748rjrlr3